These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 34393156)

  • 1. Safety and Efficacy of Zoledronic Acid Treatment with and without Acetaminophen and Eldecalcitol for Osteoporosis.
    Mochizuki T; Yano K; Ikari K; Okazaki K
    Intern Med; 2021; 60(16):2585-2591. PubMed ID: 34393156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-year effectiveness of zoledronic acid with or without eldecalcitol in Japanese patients with osteoporosis: A randomized prospective study.
    Mochizuki T; Yano K; Ikari K; Okazaki K
    Osteoporos Sarcopenia; 2022 Jun; 8(2):75-79. PubMed ID: 35832418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term efficacy and safety of zoledronate acid or denosumab in Japanese patients with postmenopausal osteoporosis.
    Nakamura Y; Shimizu T; Asano T; Shimodan S; Ishizu H; Takahashi D; Takahata M; Iwasaki N
    J Bone Miner Metab; 2021 Sep; 39(5):824-832. PubMed ID: 33821302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis.
    Sakai A; Ito M; Tomomitsu T; Tsurukami H; Ikeda S; Fukuda F; Mizunuma H; Inoue T; Saito H; Nakamura T;
    Osteoporos Int; 2015 Mar; 26(3):1193-202. PubMed ID: 25592133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of the clinical efficacy and safety of eldecalcitol for the treatment of osteoporosis.
    Cui L; Xia W; Yu C; Dong S; Pei Y
    Arch Osteoporos; 2022 May; 17(1):74. PubMed ID: 35513519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic efficacy of zoledronic acid combined with calcitriol in elderly patients receiving total hip arthroplasty or hemiarthroplasty for osteoporotic femoral neck fracture.
    Zhu K; Zhang J; Zhang C; Zhao Z; Gao J; Li X; Xia X; Xu X; Zhang T; Guan J
    Osteoporos Int; 2021 Mar; 32(3):559-564. PubMed ID: 32989470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eldecalcitol, in Combination with Bisphosphonate, Is Effective for Treatment of Japanese Osteoporotic Patients.
    Mukaiyama K; Uchiyama S; Nakamura Y; Ikegami S; Taguchi A; Kamimura M; Kato H
    Tohoku J Exp Med; 2015 Dec; 237(4):339-43. PubMed ID: 26639092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
    Orwoll ES; Miller PD; Adachi JD; Brown J; Adler RA; Kendler D; Bucci-Rechtweg C; Readie A; Mesenbrink P; Weinstein RS
    J Bone Miner Res; 2010 Oct; 25(10):2239-50. PubMed ID: 20499357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The therapeutic effect to eldecalcitol + bisphosphonate is superior to bisphosphonate alone in the treatment of osteoporosis: a meta-analysis.
    Zheng Z; Luo J
    J Orthop Surg Res; 2020 Sep; 15(1):390. PubMed ID: 32907639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effects of 12 months of monthly minodronate monotherapy and monthly minodronate combination therapy with vitamin K2 or eldecalcitol in patients with primary osteoporosis.
    Ebina K; Noguchi T; Hirao M; Kaneshiro S; Tsukamoto Y; Yoshikawa H
    J Bone Miner Metab; 2016 May; 34(3):243-50. PubMed ID: 26303222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety of eldecalcitol in Japanese patients with osteoporosis: a retrospective, large-scale database study.
    Takeuchi Y; Saito H; Makishima M; Yokoyama H; Yamaguchi T; Fujii H; Inoue E; Isemura T; Kondo S
    J Bone Miner Metab; 2022 Mar; 40(2):275-291. PubMed ID: 35041084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with zoledronic acid subsequent to odanacatib prevents bone loss in postmenopausal women with osteoporosis.
    Koldkjær Sølling AS; Harsløf T; Langdahl B
    Osteoporos Int; 2019 May; 30(5):995-1002. PubMed ID: 30656367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of osteoporosis with eldecalcitol, a new vitamin D analog: a comprehensive review and meta-analysis of randomized clinical trials.
    Xu Z; Fan C; Zhao X; Tao H
    Drug Des Devel Ther; 2016; 10():509-17. PubMed ID: 26869769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the effects of denosumab with either active vitamin D or native vitamin D on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
    Suzuki T; Nakamura Y; Tanaka M; Kamimura M; Ikegami S; Uchiyama S; Kato H
    Mod Rheumatol; 2018 Mar; 28(2):376-379. PubMed ID: 28397581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.
    Sambrook PN; Roux C; Devogelaer JP; Saag K; Lau CS; Reginster JY; Bucci-Rechtweg C; Su G; Reid DM
    Bone; 2012 Jan; 50(1):289-95. PubMed ID: 22061864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-yearly zoledronic acid in older men compared with women with recent hip fracture.
    Boonen S; Orwoll E; Magaziner J; Colón-Emeric CS; Adachi JD; Bucci-Rechtweg C; Haentjens P; Kaufman JM; Rizzoli R; Vanderschueren D; Claessens F; Sermon A; Witvrouw R; Milisen K; Su G; Lyles KW;
    J Am Geriatr Soc; 2011 Nov; 59(11):2084-90. PubMed ID: 22091563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficiency of Zoledronic Acid in Inhibiting Accelerated Periprosthetic Bone Loss After Cementless Total Hip Arthroplasty in Osteoporotic Patients: A Prospective, Cohort Study.
    Fu GT; Lin LJ; Sheng PY; Li CC; Zhang JX; Shen J; Liu S; Xue YL; Lin SP; Wang K; Zheng QJ; Ding Y
    Orthop Surg; 2019 Aug; 11(4):653-663. PubMed ID: 31456320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoledronic acid ameliorates the effects of secondary osteoporosis in rheumatoid arthritis patients.
    Xie J; Li S; Xiao L; Ouyang G; Zheng L; Gu Y; Gao C; Han X
    J Orthop Surg Res; 2019 Dec; 14(1):421. PubMed ID: 31823822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates.
    Miller PD; Pannacciulli N; Brown JP; Czerwinski E; Nedergaard BS; Bolognese MA; Malouf J; Bone HG; Reginster JY; Singer A; Wang C; Wagman RB; Cummings SR
    J Clin Endocrinol Metab; 2016 Aug; 101(8):3163-70. PubMed ID: 27270237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.